Try our Advanced Search for more refined results
Life Sciences
-
February 17, 2026
J&J Fights Beasley Allen's Bid To Pause Talc DQ Ruling
A New Jersey state court lacks standing to block an appellate panel's removal of Beasley Allen from representing hundreds of women with ovarian cancer pursuing claims against Johnson & Johnson over talcum powder, the pharmaceutical company has argued in an opposition brief.
-
February 17, 2026
Edwards Sued In Chancery Over $300M Heart Valve Earn-Out
The former shareholders of Valtech Cardio Ltd. have sued the company and its parent Edwards Lifesciences Corp. in the Delaware Chancery Court, accusing the medical device giant of deliberately stalling development of a heart valve repair system to avoid paying up to $300 million in earn-out consideration tied to the 2016 acquisition.
-
February 17, 2026
Philips Settles Suit Over Sleep Machine Starting Home Fire
Medical equipment company Philips has reached a deal with a woman who alleged in North Carolina federal court that its sleep apnea breathing machine caught fire and caused burns to her mother's face and destroyed her home.
-
February 13, 2026
RFK Jr. Taps Ex-Jones Day Atty For FDA Senior Counselor
U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. has named a former Jones Day partner as one of the U.S. Food and Drug Administration's senior counselors, according to an announcement.
-
February 13, 2026
States' Generic Drugs Antitrust Case Headed Toward Trial
A Connecticut federal judge has mostly refused to side with pharmaceutical companies facing states' generic drug price-fixing litigation against them, ruling that there are genuine disputes of material fact as to drug distribution chains and the states' antitrust standing and teeing up the case for trial.
-
February 13, 2026
Chewy Settles Antitrust Claims Over Elanco Flea & Tick Meds
Chewy has reached a settlement with consumers in a case accusing Elanco Animal Health Inc. of paying several pet supply retailers not to stock generic versions of its Advantix topical flea and tick prevention drugs.
-
February 13, 2026
Docs Urge Judge To Block CDC's Childhood Vaccine Changes
Doctors organizations Friday urged a Massachusetts federal judge to stop the government from implementing its new, shorter list of recommended vaccines for children and prevent the next meeting of a committee they say has been tainted by anti-vaccine influence.
-
February 13, 2026
Reed Smith Nabs Ex-WilmerHale Capital Markets Pro
Reed Smith LLP has hired a former WilmerHale attorney who specializes in corporate and securities matters as a global corporate group partner in Denver for the firm's business and finance department.
-
February 13, 2026
Iowa AG Urges 8th Circ. To Unblock Parts Of State PBM Law
The state of Iowa urged the Eighth Circuit on Friday to lift a preliminary block on parts of a law limiting pharmacy benefit managers' power to set drug prices in the Hawkeye State, arguing a lower court judge erred in holding that parts of the policy were federally preempted.
-
February 13, 2026
FDA Removes Boxed Warnings From HRT Products
Six menopause hormone therapies will no longer have warnings on their label about heart disease, breast cancer and dementia, after the U.S. Food and Drug Administration said it removed them so that women can make decisions "free from exaggeration or fear."
-
February 13, 2026
How Attorneys Are Handling A Patent Review 'Sea Change'
Major changes to the America Invents Act patent review system over the past year have put limits on challenges, requiring patent challengers and owners to rethink their strategies. Here's how attorneys on both sides are calibrating their arguments to have the best chance of success in the new landscape.
-
February 13, 2026
J&J Hit With $250K Verdict In 2nd Philly Talc Trial
A Philadelphia jury hit Johnson & Johnson with a $250,000 verdict on Friday, finding the company liable in the case of a woman whose family claimed that using the company's once-famous talcum powder contributed to her fatal ovarian cancer.
-
February 13, 2026
CareDx Seeks High Court Review Of $45M False Ad Case
Transplant diagnostics company CareDx has asked the U.S. Supreme Court to review a Third Circuit decision that erased a nearly $45 million jury award against rival Natera in a false advertising case, arguing the appeals court is the only one that forbids juries from inferring consumer deception when determining damages.
-
February 13, 2026
Prenatal Testing Co. Missed Fatal Condition, Couple Say
A Massachusetts couple say Natera Inc. misreported the results of tests for a genetic marker linked to a fatal kidney condition, leading to the conception of a child who died an hour after birth.
-
February 12, 2026
FTC's PBM Case Paused For More Deal Talks
Federal Trade Commission staffers are discussing potential settlements with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, following a recent deal with Express Scripts.
-
February 12, 2026
Ex-Pharma Exec Fights AGs' Quick Win Bid In Antitrust Case
A former pharmaceutical marketing executive urged a Connecticut federal court to reject summary judgment sought against him by state attorneys general pursuing wider price-fixing litigation against most of the generic drug industry, arguing key cooperating witnesses' questionable credibility makes a trial necessary.
-
February 12, 2026
Astellas Gets $120M From Zydus In Bladder Drug Deal
Generic-drug maker Zydus Pharmaceuticals has inked a $120 million deal to end a lawsuit accusing it of infringing Astellas Pharma Inc. patents covering bladder drug Myrbetriq, just two days after Lupin Pharmaceuticals made a similar deal.
-
February 12, 2026
Goodwin Expands Healthcare Team With Ex-Reed Smith Atty
A healthcare attorney specializing in guiding clients through regulatory and transactional matters has moved her practice to Goodwin Procter LLP's Philadelphia office after more than 11 years with Reed Smith LLP.
-
February 12, 2026
Regeneron, Samsung Bioepis Settle Eye Med Patent Claims
Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. Ltd. have told a West Virginia federal court they reached an agreement to end patent infringement claims brought by Regeneron over a biosimilar of its eye medication Eylea.
-
February 12, 2026
McKesson Freed From Opioid Death Suit By Ga. Panel
The Georgia Court of Appeals said Thursday that drug distributor McKesson should have been freed from a suit attempting to hold it liable for a man's opioid overdose death, saying that a trial court applied the wrong statute of limitations to what was, at its core, a personal injury claim.
-
February 11, 2026
AbbVie Sues Medicaid, HHS Over Botox Fair Price Controls
AbbVie Inc. on Wednesday asked a D.C. federal court to block the Centers for Medicare and Medicaid Services from controlling the price of Botox under the Inflation Reduction Act, arguing the cosmetic drug and migraine treatment should be excluded from the controls because it's a "plasma-derived" product.
-
February 11, 2026
Pfizer, SEC Reach $29M Deal In Insider Trading Fund Dispute
Pfizer and the U.S. Securities and Exchange Commission have jointly asked a New York federal judge to allow $29 million out of the roughly $75.2 million distribution leftover from a $602 million insider trading deal to be paid out to a Pfizer subsidiary.
-
February 11, 2026
Luxottica Franchisee Gets Another Shot At Antitrust Claims
An Ohio federal judge partially reversed course Wednesday after previously permanently tossing a Luxottica franchisee's antitrust claims, concluding that an attempt to amend them wouldn't be futile because it might be possible to show that allegedly suppressed insurance reimbursement rates were an ongoing violation that resets the statute of limitations.
-
February 11, 2026
Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now
An Illinois federal judge on Wednesday tossed out Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug Tecfidera, but said the standing issues primarily dooming their complaint can likely be cured if they amend their pleading.
-
February 11, 2026
NY Judge Rejects Bid To Stop SD Action Against Abortion Ads
A New York federal judge said Wednesday that she can't block South Dakota officials from pursuing state legal action against an abortion rights group that launched an advertising campaign in South Dakota, saying she doesn't have jurisdiction to halt the proceedings.
Expert Analysis
-
Opinion
A Uniform Federal Rule Would Curb Gen AI Missteps In Court
To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.
-
Riding The Changing Winds For AI Innovations At The USPTO
As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.
-
Series
The Law Firm Merger Diaries: Integrating Practice Groups
Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.
-
Opinion
Supreme Court Term Limits Would Carry Hidden Risk
While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.
-
Next Steps For Orgs. Amid Updated OpenAI Usage Policies
OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.
-
Series
Knitting Makes Me A Better Lawyer
Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.
-
How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation
On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.
-
Series
The Biz Court Digest: Welcome To Miami
After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.
-
Identifying And Resolving Conflicts Among Class Members
As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.
-
Adapting To A Plaintiff-Side Mindset For Patent Monetization
A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.
-
AI Evidence Rule Tweaks Encourage Judicial Guardrails
Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.
-
Series
The Law Firm Merger Diaries: Getting The Message Across
Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.
-
Opinion
Horizontal Stare Decisis Should Not Be Casually Discarded
Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.
-
10 Commandments For Agentic AI Tools In The Legal Industry
Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.
-
Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims
The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.